Safety, efficacy balance needed for ROP treated with bevacizumab

WAILEA, Hawaii — A balance between safety and efficacy is needed when deciding whether to treat retinopathy of prematurity with bevacizumab or diode laser photocoagulation in premature newborns, a speaker here said.
Bevacizumab is a powerful suppressive agent given during a time when a lot of organ systems are developing, peaking in the systemic circulation around 2 weeks and lasting to about 8 weeks in systemic circulation, Darius M. Moshfeghi, MD, said at Retina 2018. Furthermore, neurodevelopmental abnormalities have been noted in small sick babies receiving bevacizumab in some